Dengue Vaccines Market Size, Trends & Forecast by 2033 | FMI
Future Market Insights (FMI), a leading market research firm, has unveiled a comprehensive analysis forecasting promising prospects for the Global Dengue Vaccines Industry. The study anticipates substantial advancements in the sector, with projections indicating a remarkable growth trajectory surpassing US$ 1603.7 million by the year 2033, driven by a robust double-digit Compound Annual Growth Rate (CAGR).
Key pharmaceutical companies, having successfully concluded clinical trials, are gearing up for potential new product launches. Analysts express optimism about the imminent expansion of the growth horizon within the Dengue vaccine industry. The strategic insights provided by FMI underscore the industry’s potential to address the rising prevalence of dengue fever, particularly in the Asia-Pacific region.
The Asia-Pacific region has witnessed a surge in the incidence of dengue fever, escalating the demand for effective medicines and vaccines to combat this viral disease. Against this backdrop, some pharmaceutical companies are focusing on the development of innovative dengue vaccines. FMI’s latest report highlights a positive trajectory for the Global Dengue Vaccines Industry, with a projected total valuation of US$ 474.8 million expected in 2023.
Request a Sample of this Report Now!
https://www.futuremarketinsigh....ts.com/reports/sampl
Geographic Overview
Latin America is expected to remain the second largest market for dengue vaccines, with a valuation of nearly US$ 290 million by the end of the forecast period. The report also predicts that more pharmaceutical companies will become involved in the expansion of the Global Dengue vaccine industry shortly.
According to the report, government institutes will continue to be the largest end-users of dengue vaccines. Dengue vaccine sales across government institutes will generate nearly US$650 million in revenue by the end of 2027. Furthermore, hospitals will maintain their dominance, with double-digit CAGRs throughout the forecast period. Sales of the sole vaccine, Dengvaxia, manufactured by Sanofi, are currently driving market growth. Furthermore, the factors influencing the market growth profiled in the report are discussed below.
Key Highlights of Global Dengue Vaccines Industry Report
Other than the burdening occurrence of dengue in some countries, the economic turmoil in Latin America is estimated to influence the growth of the global market at the macroeconomic level.
Live attenuated vaccines are also produced and developed economically, thereby consoling the vaccine market and patients.
Low availability of optimum diagnostic systems and lack of skilled professionals have led to cases, where dengue fever is being treated as undistinguished febrile disease.
The global market of dengue vaccines is likely to secure an opportunistic revolution when companies are likely to able to successfully develop effective vaccines for all age groups.
Overall, the global dengue vaccines market, which is currently valued at nearly US$ 250 million, will increase rapidly to reach over US$ 1,250 million in terms of revenues, by the end of 2027.
Discovering the assumptions behind the study. Talk to Analyst
https://www.futuremarketinsigh....ts.com/ask-question/
According to FMI’s report, the following dengue vaccine manufacturers operate within the Global Dengue Vaccines Industry landscape:
Sanofi Pasteur Limited
Takeda Pharmaceutical Company Limited
Merck & Co. Inc.
GlaxoSmithKline Plc.
GeneOne Life Science Inc.
Medigen Vaccine Biologics Corporation
Panacea Biotec Limited
Sun Pharmaceutical Industries Ltd
Serum Institute of India Pvt. Ltd.
Biological E Ltd.
Global Dengue Vaccines Industry Key Segments Covered
Product
CYD-TDV (Dengvaxia)
End-User
Hospitals
Government Institutes
Non-governmental Organizations (NGOs)
Region
North America (US and Canada)
Latin America (Brazil, Mexico, Venezuela and Rest of LATAM)
Western Europe (Germany, UK, France, Spain, Italy and Rest of Western Europe)
Eastern Europe (Russia, Poland and Rest of Eastern Europe)
APEJ (The Philippines, Indonesia, Malaysia, Thailand, Vietnam, India and Rest of APEJ)
Japan
Middle East & Africa (GCC, Northern Africa, South Africa and Rest of MEA)
